|  |  |  | AUC |
---|
cohort
|
regimen
|
patients
|
responders
|
CEI1
|
CEI2
|
CEI3
|
CEI4
|
CEI5
|
CEI6
|
EORTC | FEC | 37 | 16 | 0.73R* | 0.57 | 0.51R | 0.61 | 0.56 | 0.54 |
MDA1 | TFAC | 27 | 13 | 0.78 ** | 0.62 | 0.77** | 0.61R | 0.53 | 0.61 |
MDA/MAQC | TFAC | 30 | 9 | 0.77* | 0.66 | 0.78* | 0.62R | 0.58 | 0.54 |
DFCI2 | P | 24 | 4 | 0.73 | 0.72R | 0.50 | 0.52R | 0.52R | 0.57R |
JBI2 | E | 43 | 4 | 0.85R* | 0.73R | 0.53 | 0.88** | 0.58R | 0.72 |
- Each CEI was evaluated as a univariate predictor of pathological complete response or residual disease using the area under the ROC curve (AUC). Chemotherapy regimens are indicated: A, doxorubicin; C, cyclophosphamide; E, epirubicin; F, 5-fluorouracil; P, either cisplatin or carboplatin; T, either paclitaxel or docetaxel. The CEIs were derived from four independent DNBC cohorts not shown in this table. * P < 0.05; ** P < 0.01. R: AUC is estimated based on association to residual disease (RD).